{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:47:56Z","timestamp":1787032076258,"version":"build-2736575974"},"reference-count":105,"publisher":"Japan Atherosclerosis Society","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAT"],"published-print":{"date-parts":[[2013]]},"DOI":"10.5551\/jat.19281","type":"journal-article","created":{"date-parts":[[2013,8,19]],"date-time":"2013-08-19T19:09:51Z","timestamp":1376939391000},"page":"743-754","source":"Crossref","is-referenced-by-count":43,"title":["Pathogenic Role of Modified LDL Antibodies and Immune Complexes in Atherosclerosis"],"prefix":"10.5551","volume":"20","author":[{"given":"Maria F.","family":"Lopes-Virella","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Virella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3489","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Libby P: Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol, 2012; 32: 2045-2051","DOI":"10.1161\/ATVBAHA.108.179705"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Ketelhuth DF, Hansson GK: Cellular immunity, lowdensity lipoprotein and atherosclerosis: Break of tolerance in the artery wall. Thromb Haemost, 2011; 106: 779-786","DOI":"10.1160\/TH11-05-0321"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Lundberg AM, Hansson GK: Innate immune signals in atherosclerosis. Clin Immunol, 2010; 134: 5-24","DOI":"10.1016\/j.clim.2009.07.016"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Andersson J, Libby P, Hansson GK: Adaptive immunity and atherosclerosis. Clin Immunol, 2010; 134: 33-46","DOI":"10.1016\/j.clim.2009.07.002"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Lopes-Virella MF, Virella G: Clinical significance of the humoral immune response to modified LDL. Clin Immunol, 2010; 134: 55-65","DOI":"10.1016\/j.clim.2009.04.001"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Penn MS, Chisolm GM: Oxidized lipoproteins, altered cell function and atherosclerosis. Atherosclerosis, 1994; 108: S21-29","DOI":"10.1016\/0021-9150(94)90150-3"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Henriksen T, Mahoney ME, Steinberg D: Enhanced macrophage degradation of biologically modified low density lipoprotein. Arteriosclerosis, 1983; 3: 149-158","DOI":"10.1161\/01.ATV.3.2.149"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Arai K, Kita T, Yokode M, Narumiya S, Kawai C: Multiple receptors for modified LDL in mouse peritoneal macrophages: Different uptake mechanisms for acetylated and oxidized LDL. Biochem Biophys Res Commun, 1989; 159: 1375-1379","DOI":"10.1016\/0006-291X(89)92262-6"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Endemann G, Stanton LW, Madden KS, Bryant CM, White RT, Protter AA: Cd36 is a receptor for oxidized LDL. J Biol Chem, 1993; 268: 11811-11818","DOI":"10.1016\/S0021-9258(19)50272-1"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Sparrow CP, Parthasarathy S, Steinberg D: A macrophage receptor that recognizes oxidized low density lipoprotein but not acetylated low density lipoprotein. J Biol Chem, 1989; 264: 2599-2604","DOI":"10.1016\/S0021-9258(19)81655-1"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Li W, Febbraio M, Reddy SP, Yu DY, Yamamoto M, Silverstein RL: Cd36 participates in a signaling pathway that regulates ROS formation in murine VSMCs. J Clin Invest, 2010; 120: 3996-4006","DOI":"10.1172\/JCI42823"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Quinn MT, Parthasarathy S, Fong LG, Steinberg D: Oxidatively modified low density lipoproteins: A potential role in recruitment and retention of monocyte\/macrophages during atherogenesis. Proc Nat Acad Sci USA, 1987; 84: 2995-299","DOI":"10.1073\/pnas.84.9.2995"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Quinn MT, Parthasarathy S, Steinberg D: Endothelial cell-derived chemotactic activity for mouse peritoneal macrophages and the effects of modified forms of lowdensity lipoprotein. 82: 5949-5953, 1985. Proc Natl Acad Sci USA, 1985; 82: 5949-5953","DOI":"10.1073\/pnas.82.17.5949"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Berliner JA, Territo MC, Sevanian A, Raimin S, Kim JA, Bamshad B, Ester-son M, Fogelman AM: Minimally modified low density lipoprotein stimulates monocyte endothelial interactions. J Clin Invest, 1990; 85: 1260-1266","DOI":"10.1172\/JCI114562"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Kume N, Cybulsky MI, Gimbrone MAJ: Lysophosphatidyl-choline, a component of atherogenic lipoproteins, induces mononuclear leukocyte adhesion molecules in cultured human and rabbit arterial endothelial cells. J Clin Invest, 1992; 90: 1138-1144","DOI":"10.1172\/JCI115932"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Kahn BV, Parthasarathy SS, Alexander RW, Medford RM: Modified LDL and its constituents augment cytokine-activated vascular cell adhesion molecule -1 gene expression in human vascular endothelial cells. J Clin Invest, 1995; 95: 1262-1270","DOI":"10.1172\/JCI117776"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Takei A, Huang Y, Lopes-Virella MF: Expression of adhesion molecules by human endothelial cells exposed to oxidized low density lipoprotein. Influences of degree of oxidation and location of oxidized LDL. Atherosclerosis, 2001; 154: 79-86","DOI":"10.1016\/S0021-9150(00)00465-2"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Svensson PA, Asea A, Englund MC, Bausero MA, Jernas M, Wiklund O, Ohlsson BG, Carlsson LM, Carlsson B: Major role of hsp70 as a paracrine inducer of cytokine production in human oxidized LDL treated macrophages. Atherosclerosis, 2006; 185: 32-38","DOI":"10.1016\/j.atherosclerosis.2005.05.007"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Vlassara H, Cai W, Crandall J, Goldberg T, Oberstein R, Dardaine V, Peppa M, Rayfield EJ: Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy. Proc Natl Acad Sci U S A, 2002; 99: 15596-15601","DOI":"10.1073\/pnas.242407999"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Wendt T, Bucciarelli L, Qu W, Lu Y, Yan SF, Stern DM, Schmidt AM: Receptor for advanced glycation endproducts (RAGE) and vascular inflammation: Insights into the pathogenesis of macrovascular complications in diabetes. Curr Atheroscler Rep, 2002; 4: 228-237","DOI":"10.1007\/s11883-002-0024-4"},{"key":"21","unstructured":"21) Vlassara H, Bucala R, Striker L: Pathogenic effects of advanced glycosylation: Biochemical, biologic, and clinical implications for diabetes and aging. Lab Invest, 1994; 70: 138-151"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Schmidt AM, Hori O, Chen JX, Li JF, Crandall J, Zhang J, Cao R, Yan SD, Brett J, Stern D: Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes. J Clin Invest, 1995; 96: 1395-1403","DOI":"10.1172\/JCI118175"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Steinbrecher UP, Fisher M, Witztum JL, Curtiss LK: Immunogenicity of homologous low density lipoprotein after methylation, ethylation, acetylation, or carbamylation: Generation of antibodies specific for derivatized lysine. J Lipid Res, 1984; 25: 1109-1116","DOI":"10.1016\/S0022-2275(20)37720-8"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Palinski W, Yla-Herttuala S, Rosenfeld ME, Butler SW, Socher SA, Parthasarathy S, Curtiss LK, Witztum JL: Antisera and monoclonal antibodies specific for epitopes generated during oxidative modification of low density lipoprotein. Arteriosclerosis, 1990; 10: 325-335","DOI":"10.1161\/01.ATV.10.3.325"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Steinbrecher UP: Oxidation of human low density lipoprotein results in derivatization of lysine residues of apolipoprotein B by lipid peroxide decomposition products. J Biol Chem, 1987; 262: 3603-3608","DOI":"10.1016\/S0021-9258(18)61395-X"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Mironova M, Virella G, Lopes-Virella MF: Isolation and characterization of human antioxidized LDL autoantibodies. Arterioscler Thromb Vasc Biol, 1996; 16: 222- 229","DOI":"10.1161\/01.ATV.16.2.222"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Virella G, Thorpe SR, Alderson NL, Stephan EM, Atchley DH, Wagner F, Lopes-Virella MF, Group DER: Autoimmune response to advanced glycosylation endproducts of human low density lipoprotein. J Lipid Res, 2003; 443: 487-493","DOI":"10.1194\/jlr.M200370-JLR200"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Atchley DH, Lopes-Virella MF, Zheng D, Virella G: Oxidized LDL-anti-oxidized LDL immune complexes and diabetic nephropathy. Diabetologia, 2002; 45: 1562-1571","DOI":"10.1007\/s00125-002-0962-y"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Virella G, Lopes-Virella MF: Lipoprotein autoantibodies: Measurement and significance. Clin Diagn Lab Immunol, 2003; 10: 499-505","DOI":"10.1128\/CDLI.10.4.499-505.2003"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Virella G, Thorpe S, Alderson NL, Derrick MB, Chassereau C, Rhett JM, Lopes-Virella MF: Definition of the immunogenic forms of modified human LDL recognized by human autoantibodies and by rabbit hyperimmune antibodies. J Lipid Res, 2004; 45: 1859-1867","DOI":"10.1194\/jlr.M400095-JLR200"},{"key":"31","unstructured":"31) Beaumont J: Autoimmune hyperlipidemia. An atherogenic metabolic disease of immune origin. Rev Eur Stud Clin Biol, 1970; 15: 1037-1041"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) F\u00fcst G, Szondy E, Szekely J, Nanai I, Ger\u00f6 S: Studies on the occurrence of circulating immune complexes in vascular disease. Atherosclerosis, 1978; 29: 181-190","DOI":"10.1016\/0021-9150(78)90006-0"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Klimov AN, Denisenko AD, Popov AV, Nagornev VA, Pleskov VM, Vinogradov AG, Denisenko TV, Magracheva E, Kheifes GM, Kuznetzov AS: Lipoprotein-antibody immune complexes: Their catabolism and role in foam cell formation. Atherosclerosis, 1985; 58: 1-15","DOI":"10.1016\/0021-9150(85)90051-6"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Griffith RL, Virella GT, Stevenson HC, Lopes-Virella MF: Low density lipoprotein metabolism by human macrophages activated with low density lipoprotein immune complexes. A possible mechanism of foam cell formation. J Exp Med, 1988; 168: 1041-1059","DOI":"10.1084\/jem.168.3.1041"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Klimov AN, Denisenko AD, Vinogradov AG, Nagornev VA, Pivovarova YI, Sitnikova OD, Pleskov VM: Accumulation of cholesteryl esters in macrophages incubated with human lipoprotein-antibody autoimmune complex. Atherosclerosis, 1988; 74: 41-46","DOI":"10.1016\/0021-9150(88)90189-X"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Lopes-Virella MF, Griffith RL, Shunk KA, Virella GT: Enhanced uptake and impaired intracellular metabolism of low density lipoprotein complexed with anti-low density lipoprotein antibodies. Arterioscler Thromb, 1991; 11: 1356-1367","DOI":"10.1161\/01.ATV.11.5.1356"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Lopes-Virella MF, Binzafar N, Rackley S, Takei A, La Via M, Virella G: The uptake of LDL-IC by human macrophages: Predominant involvement of the Fc gamma RI receptor. Atherosclerosis, 1997; 135: 161-170","DOI":"10.1016\/S0021-9150(97)00157-3"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) Abdelsamie SA, Li Y, Huang Y, Lee M-H, Klein RL, Virella G, Lopes-Virella MF: Oxidized LDL immune complexes stimulate collagen IV production in mesangial cells via Fc gamma receptor I. Clin Immunol, 2011; 139: 258-266","DOI":"10.1016\/j.clim.2011.01.016"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39) Saad AF, Virella G, Chassereau C, Boackle RJ, LopesVirella MF: OxLDL immune complexes activate com plement and induce cytokine production by monomac 6 cells and human macrophages. J Lipid Res, 2006; 47: 1975-1983","DOI":"10.1194\/jlr.M600064-JLR200"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40) Huang Y, Fleming AJ, Wu S, Virella G, Lopes-Virella MF: Fc-gamma receptor cross-linking by immune complexes induces matrix metalloproteinase-1 in U937 cells via mitogen-activated protein kinase. Arterioscler Thromb Vasc Biol, 2000; 20: 2533-2538","DOI":"10.1161\/01.ATV.20.12.2533"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41) Nagarajan S: Anti-oxLDL IgG blocks oxLDL interaction with CD36, but promotes FcgR, CD32a-dependent inflammatory cell adhesion. Immunol Lett, 2007; 108: 52-61","DOI":"10.1016\/j.imlet.2006.09.008"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42) Morganelli PM, Kitzmiller TJ, Hemmer R, Fanger MW: Redirected targeting of LDL to human monocyte Fcg receptors with bispecific antibodies. Arterioscler Thromb, 1992; 12: 1131-1138","DOI":"10.1161\/01.ATV.12.10.1131"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43) Virella G, Munoz JF, Galbraith GM, Gissinger C, Chassereau C, Lopes-Virella MF: Activation of human monocyte-derived macrophages by immune complexes containing low-density lipoprotein. Clin Immunol Immunopath, 1995; 75: 179-189","DOI":"10.1006\/clin.1995.1069"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44) Kiener PA, Rankin BM, Davis PM, Yocum SA, Warr GA, Grove RI: Immune complexes of LDL induce atherogenic responses in human monocytic cells. Arterioscler Thromb Vasc Biol, 1995; 15: 990-999","DOI":"10.1161\/01.ATV.15.7.990"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45) Gisinger C, Virella GT, Lopes-Virella MF: Erythrocytebound low-density lipoprotein immune complexes lead to cholesteryl ester accumulation in human monocytederived macrophages. Clin Immunol Immunopath, 1991; 59: 37-52","DOI":"10.1016\/0090-1229(91)90080-T"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46) Virella G, Atchley DH, Koskinen S, Zheng D, Lopes-Virella M: Pro-atherogenic and pro-inflammatory properties of immune complexes prepared with purified human oxLDL antibodies and human oxLDL. Clin Immunol, 2002; 105: 81-92","DOI":"10.1006\/clim.2002.5269"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47) Oksjoki R, Kovanen PT, Lindstedt KA, Jansson B, Pentikainen MO: OxLDL-IgG immune complexes induce survival of human monocytes. Arterioscler Thromb Vasc Biol, 2006; 26: 576-583","DOI":"10.1161\/01.ATV.0000201041.14438.8d"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48) Hammad SM, Twal WO, Barth JL, Smith KJ, Saad AF, Virella G, Argraves WS, Lopes-Virella MF: Oxidized LDL immune complexes and oxidized LDL differentially affect the expression of genes involved with inflammation and survival in human U937 monocytic cells. Atherosclerosis, 2009; 202: 394-404","DOI":"10.1016\/j.atherosclerosis.2008.05.032"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49) Truman JP, Al Gadban MM, Smith KJ, Jenkins RW, Mayroo N, Virella G, Lopes-Virella MF, Bielawska A, Hannun YA, Hammad SM: Differential regulation of acid sphingomyelinase in macrophages stimulated with oxidized low-density lipoprotein (LDL) and oxidized LDL immune complexes: Role in phagocytosis and cytokine release. Immunology, 2012; 136: 30-45","DOI":"10.1111\/j.1365-2567.2012.03552.x"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50) Al Gadban MM, Smith KJ, Soodavar F, Piansay C, Chassereau C, Twal WO, Klein RL, Virella G, Lopes-Virella MF, Hammad SM: Differential trafficking of oxidized LDL and oxidized LDL immune complexes in macrophages: Impact on oxidative stress. PLoS One, 2010; 5","DOI":"10.1371\/journal.pone.0012534"},{"key":"51","unstructured":"51) Virella G, LI Y, Huang Y, Lopes-Virella M: The nature of modified LDL involved in the formation of immune complexes has a modulating effect on macrophage activation. FOCIS 2012. 2012; Abstract supplement: 94-95"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52) Yla-Herttuala S, Palinski W, Rosenfeld ME, Parthasarathy S, Carew TE, Butler S, Witztum JL, Steinberg D: Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest, 1989; 84: 1086-1095","DOI":"10.1172\/JCI114271"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53) Yla-Herttuala S, Palinski W, Rosenfeld ME, Steinberg D, Witztum JL: Lipoproteins in normal and atherosclerotic aorta. European Heart J, 1990; 11: 88-89","DOI":"10.1093\/eurheartj\/11.suppl_E.88"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54) Yla-Herttuala S: Macrophages and oxidized low density lipoproteins in the pathogenesis of atherosclerosis. Ann Med, 1991; 23: 561-567","DOI":"10.3109\/07853899109150518"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55) Yla-Herttuala S, Palinski W, Butler S, Picard S, Steinberg D, Witztum JL: Rabbit and human atherosclerotic lesions contain igg that recognizes epitopes of oxidized LDL. Arterioscler Thromb, 1994; 14: 32-40","DOI":"10.1161\/01.ATV.14.1.32"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56) Turk Z, Ljubic S, Turk N, Benko B: Detection of autoantibodies against advanced glycation endproducts and age-immune complexes in serum of patients with diabetes mellitus. Clin Chim Acta, 2001; 303","DOI":"10.1016\/S0009-8981(00)00389-2"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57) Bevan RJ, Durand MF, Hickenbotham PT, Kitas GD, Patel PR, Podmore ID, Griffiths HR, Waller HL, Lunec J: Validation of a novel ELISA for measurement of MDA-LDL in human plasma. Free Radic Biol Med, 2003; 35: 517-527","DOI":"10.1016\/S0891-5849(03)00359-9"},{"key":"58","doi-asserted-by":"crossref","unstructured":"58) Holvoet P, Perez G, Zhao Z, Brouwers E, Bernar H, Collen D: Malondialdehyde-modified low density lipoproteins in patients with atherosclerotic disease. J Clin Invest, 1995; 95: 2611-2619","DOI":"10.1172\/JCI117963"},{"key":"59","doi-asserted-by":"crossref","unstructured":"59) Hulthe J, Wikstrand J, Lidell A, Wendelhag I, Hansson GK, Wiklund O: Antibody titers against oxidized LDL are not elevated in patients with familial hypercholesterolemia. Arterioscler Thromb Vasc Biol, 1998; 18: 1203-1211","DOI":"10.1161\/01.ATV.18.8.1203"},{"key":"60","doi-asserted-by":"crossref","unstructured":"60) van de Vijver LP, Steyger R, van Poppel G, Boer JM, Kruijssen DA, Seidell JC, Princen HM: Autoantibodies against MDA-LDL in subjects with severe and minor atherosclerosis and healthy population controls. Atherosclerosis, 1996; 122: 245-253","DOI":"10.1016\/0021-9150(95)05759-5"},{"key":"61","doi-asserted-by":"crossref","unstructured":"61) Tsimikas S, Palinski W, Witztum JL: Circulating autoantibodies to oxidized LDL correlate with arterial accumulation and depletion of oxidized LDL in LDL receptordeficient mice. Arterioscler Thromb Vasc Biol, 2001; 21: 95-100","DOI":"10.1161\/01.ATV.21.1.95"},{"key":"62","doi-asserted-by":"crossref","unstructured":"62) Lopes-Virella MF, Virella G, Orchard TJ, Koskinen S, Evans RW, Becker DJ, Forrest KY: Antibodies to oxidized LDL and LDL-containing immune complexes as risk factors for coronary artery disease in diabetes mellitus. Clin Immunol, 1999; 90: 165-172","DOI":"10.1006\/clim.1998.4631"},{"key":"63","doi-asserted-by":"crossref","unstructured":"63) Mironova M, Virella G, Virella-Lowell I, Lopes-Virella MF: Anti-modified LDL antibodies and LDL-containing immune complexes in IDDM patients and healthy controls. Clin Immunol Immunopath, 1997; 85: 73-82","DOI":"10.1006\/clin.1997.4404"},{"key":"64","doi-asserted-by":"crossref","unstructured":"64) Turk Z, Sesto M, Skodlar J, Ferencak G, Turk N, Stavljenic-Rukavina A: Soluble LDL-immune complexes in type 2 diabetes and vascular disease. Horm Metab Res, 2002; 34: 196-201","DOI":"10.1055\/s-2002-26706"},{"key":"65","doi-asserted-by":"crossref","unstructured":"65) Virella G, Derrick MB, Pate V, Chassereau C, Thorpe SR, Lopes-Virella MF: Development of capture assays for different modifications of human low-density lipoprotein. Clin Diagn Lab Immunol, 2005; 12: 68-75","DOI":"10.1128\/CDLI.12.1.68-75.2005"},{"key":"66","unstructured":"66) Zubler RH, Perin LH, Creighton WD, Lambert PH: Use of polyethylene glycol (PEG) to concentrate immune complexes from serum or plasma samples. Ann Rheum Dis, 1977; 36 (Suppl.): 23-26"},{"key":"67","doi-asserted-by":"crossref","unstructured":"67) Amir S, Binder CJ: Experimental immunotherapeutic approaches for atherosclerosis. Clin Immunol, 2010; 134: 66-79","DOI":"10.1016\/j.clim.2009.07.009"},{"key":"68","doi-asserted-by":"crossref","unstructured":"68) Freigang S, Horkko S, Miller E, Witztum JL, Palinski W: Immunization of LDL receptor-deficient mice with homologous malondialdehyde-modified and native LDL reduces progression of atherosclerosis by mechanisms other than induction of high titers of antibodies to oxidative neoepitopes. ArteriosclerThromb Vasc Biol, 1998; 18: 1972-1982","DOI":"10.1161\/01.ATV.18.12.1972"},{"key":"69","doi-asserted-by":"crossref","unstructured":"69) Palinski W, Tangirala RK, Miller E, Young SG, Witztum JL: Increased autoantibody titers against epitopes of oxidized LDL in LDL receptor-deficient mice with increased atherosclerosis. Arterioscler Thromb Vasc Biol, 1995; 15: 1569-1576","DOI":"10.1161\/01.ATV.15.10.1569"},{"key":"70","doi-asserted-by":"crossref","unstructured":"70) Virella G, Lopes-Virella MF: Humoral immunity and atherosclerosis. Nature Medicine, 2003; 9: 243-244","DOI":"10.1038\/nm0303-243"},{"key":"71","doi-asserted-by":"crossref","unstructured":"71) Davis MM: A prescription for human immunology. Immunity, 2008; 29: 835-838","DOI":"10.1016\/j.immuni.2008.12.003"},{"key":"72","unstructured":"72) Turner MW: Structure and function of immunoglobulins. In: Glynn LE, Steward MM, eds. Immunochemistry: An advanced textbook. New York: J. Wiley and Sons; 1977: 1-57"},{"key":"73","doi-asserted-by":"crossref","unstructured":"73) Boackle RJ: The complement system. In: Virella G, ed. Medical immunology. NY and London: Informa; 2007: 93-112","DOI":"10.3109\/9781420020878-10"},{"key":"74","doi-asserted-by":"crossref","unstructured":"74) Karvonen J, Paivansalo M, Kesaniemi YA, Horkko S: Immunoglobulin m type of autoantibodies to oxidized low-density lipoprotein has an inverse relation to carotid artery atherosclerosis. Circulation, 2003; 108: 2107-2112. Epub 2003 Oct 2106","DOI":"10.1161\/01.CIR.0000092891.55157.A7"},{"key":"75","doi-asserted-by":"crossref","unstructured":"75) Su J, Georgiades A, Wu R, Thulin T, de Faire U, Frostegard J: Antibodies of igm subclass to phosphorylcholine and oxidized LDL are protective factors for atherosclerosis in patients with hypertension. Atherosclerosis, 2006; 188: 160-166","DOI":"10.1016\/j.atherosclerosis.2005.10.017"},{"key":"76","doi-asserted-by":"crossref","unstructured":"76) Tsimikas S, Brilakis ES, Lennon RJ, Miller ER, Witztum JL, McConnell JP, Kornman KS, Berger PB: Relationship of IgG and IgM autoantibodies to oxidized low density lipoprotein with coronary artery disease and cardiovascular events. J Lipid Res, 2007; 48: 425-433","DOI":"10.1194\/jlr.M600361-JLR200"},{"key":"77","doi-asserted-by":"crossref","unstructured":"77) Fredrikson GN, Hedblad B, Berglund G, Alm R, Nilsson JA, Schiopu A, Shah PK, Nilsson J: Association between igm against an aldehyde-modified peptide in apolipoprotein B-100 and progression of carotid disease. Stroke, 2007; 38: 1495-1500","DOI":"10.1161\/STROKEAHA.106.474577"},{"key":"78","doi-asserted-by":"crossref","unstructured":"78) Virella G, Colglazier J, Chassereau C, Hunt KJ, Baker NL, Lopes-Virella MF: Immunoassay of modified forms of human low density lipoprotein in isolated circulating immune complexes. J Immunoassay Immunochem, 2013; 34: 61-74","DOI":"10.1080\/15321819.2012.683500"},{"key":"79","doi-asserted-by":"crossref","unstructured":"79) Lopes-Virella MF, Baker NL, Hunt KJ, Virella G, and Moritz T for the VADT Group of Investigators: The levels of MDA - LDL in circulating immune complexes predict myocardial infarction in the VADT study Atherosclerosis, 2012; 224: 526-532","DOI":"10.1016\/j.atherosclerosis.2012.08.006"},{"key":"80","doi-asserted-by":"crossref","unstructured":"80) Holvoet P, Stassen JM, Van Cleemput J, Collen D, Vanhaecke J: Oxidized low density lipoproteins in patients with transplant-associated coronary artery disease. Arterioscler Thromb Vasc Biol, 1998; 18: 100-107","DOI":"10.1161\/01.ATV.18.1.100"},{"key":"81","doi-asserted-by":"crossref","unstructured":"81) Toshima S, Hasegawa A, Kurabayashi M, Itabe H, Takano T, Sugano J, Shimamura K, Kimura J, Michishita I, Suzuki T, Nagai R: Circulating oxidized low density lipoprotein levels. A biochemical risk marker for coronary heart disease. Arterioscler Thromb Vasc Biol, 2000; 20: 2243-2247","DOI":"10.1161\/01.ATV.20.10.2243"},{"key":"82","doi-asserted-by":"crossref","unstructured":"82) Huang H, Mai W, Liu D, Hao Y, Tao J, Dong Y: The oxidation ratio of LDL: A predictor for coronary artery disease. Dis Markers, 2008; 24: 341-349","DOI":"10.1155\/2008\/371314"},{"key":"83","doi-asserted-by":"crossref","unstructured":"83) Anselmi M, Garbin U, Agostoni P, Fusaro M, Pasini AF, Nava C, Keta D, Turri M, Zardini P, Vassanelli C, Lo Cascio V, Cominacini L: Plasma levels of oxidized-lowdensity lipoproteins are higher in patients with unstable angina and correlated with angiographic coronary complex plaques. Atherosclerosis, 2006; 185: 114-120","DOI":"10.1016\/j.atherosclerosis.2005.05.020"},{"key":"84","doi-asserted-by":"crossref","unstructured":"84) Yamashita H, Ehara S, Yoshiyama M, Naruko T, Haze K, Shirai N, Sugama Y, Ikura Y, Ohsawa M, Itabe H, Kataoka T, Kobayashi Y, Becker AE, Yoshikawa J, Ueda M: Elevated plasma levels of oxidized low-density lipoprotein relate to the presence of angiographically detected complex and thrombotic coronary artery lesion morphology in patients with unstable angina. Circ J, 2007; 71: 681-687","DOI":"10.1253\/circj.71.681"},{"key":"85","doi-asserted-by":"crossref","unstructured":"85) Niccoli G, Mongiardo R, Lanza GA, Ricco A, Burzotta F, Trani C, Mazzari MA, Liuzzo G, Lombardo A, Rebuzzi AG, Holvoet P, Crea F: The complex link between oxidised low-density lipoprotein and unstable angina. J Cardiovasc Med (Hagerstown), 2007; 8: 387-391","DOI":"10.2459\/01.JCM.0000268127.36295.04"},{"key":"86","doi-asserted-by":"crossref","unstructured":"86) Holvoet P, Jenny NS, Schreiner PJ, Tracy RP, Jacobs DR: The relationship between oxidized LDL and other cardiovascular risk factors and subclinical cvd in different ethnic groups: The multi-ethnic study of atherosclerosis (mesa). Atherosclerosis, 2007; 194: 245-252","DOI":"10.1016\/j.atherosclerosis.2006.08.002"},{"key":"87","doi-asserted-by":"crossref","unstructured":"87) Romano EL, Sotolongo-Pons M, Camejo G, Soyano A: Circulating immune complexes, immunoglobulins, complement, antibodies to dietary antigens, cholesterol and lipoproteins levels in patients with occlusive coronary lesions. Atherosclerosis, 1984; 53: 119-128","DOI":"10.1016\/0021-9150(84)90189-8"},{"key":"88","unstructured":"88) Smith GW, McArthur CJ, Simpson IJ: Circulating immune complexes in myocardial infarction. J Clin Lab Immunol, 1983; 12: 197-199"},{"key":"89","doi-asserted-by":"crossref","unstructured":"89) Virella G, Wohltmann H, Sagel J, Lopes-Virella MF, Kilpatrick M, Phillips C, Colwell J: Soluble immune complexes in patients with diabetes mellitus: Detection and pathological significance. Diabetologia, 1981; 21: 184-191","DOI":"10.1007\/BF00252652"},{"key":"90","doi-asserted-by":"crossref","unstructured":"90) Orekhov AN, Kalenich OS, Tetov VV, Novikov ID, Vorobeva EG: Cholesterol level in circulating immune complexes as a marker of coronary atherosclerosis. In: Malmendier CL, ed. Hypercholesterolemia, hypochlesterolemia, hypertriglyceridemia. New York: Plenum Press; 1990: 393-397","DOI":"10.1007\/978-1-4684-5904-3_47"},{"key":"91","doi-asserted-by":"crossref","unstructured":"91) Tertov VV, Orekhov AN, Kacharava AG, Sobenin IA, Perova NV, Smirnov VN: Low density lipoprotein-containing circulating immune complexes and coronary atherosclerosis. Exp Mol Path, 1990; 52: 300-308","DOI":"10.1016\/0014-4800(90)90071-K"},{"key":"92","doi-asserted-by":"crossref","unstructured":"92) Szondy E, Horvath M, Mezey Z, Szekely J, Lengyel E, Fust G, Gero S: Free and complexed anti-lipoprotein antibodies in vascular diseases. Atherosclerosis, 1983; 49: 69-77","DOI":"10.1016\/0021-9150(83)90008-4"},{"key":"93","doi-asserted-by":"crossref","unstructured":"93) Boullier A, Hamon M, Walters-Laporte E, MartinNizart F, Mackereel R, Fruchart JC, Bertrand M, Duriez P: Detection of autoantibodies against oxidized lowdensity lipoproteins and of IgG-bound lowdensity lipoproteins in patients with coronary artery disease. Clin Chim Acta, 1995; 238: 1-10","DOI":"10.1016\/0009-8981(95)06054-H"},{"key":"94","doi-asserted-by":"crossref","unstructured":"94) Wu R, de Faire U, Lemne C, Witztum JL, Frostegard J: Autoantibodies to oxLDL are decreased in individuals with borderline hypertension. Hypertension, 1999; 33: 53-59","DOI":"10.1161\/01.HYP.33.1.53"},{"key":"95","doi-asserted-by":"crossref","unstructured":"95) Salonen E-M, Vaheri A, Suni J, Wagger O: Rheumatoid factor in acute viral infections: Interference with determination of IgM, IgG, and IgA antibodies in an enzyme immunoassay J Inf Dis, 1980; 142: 250-255","DOI":"10.1093\/infdis\/142.2.250"},{"key":"96","doi-asserted-by":"crossref","unstructured":"96) TIinahones FJ, Gomez-Zumaquero JM, Garrido-Sanchez Garcia-Fuentes E, Rojo-Martinez G, Esteva I, de dana MS, Cardona F, Soriguer F: Influence of age and on levels of anti-oxidized LDL antibodies and anti-LDL immune complexes in the general population. Journal of lipid research, 2005; 46: 452-457","DOI":"10.1194\/jlr.M400290-JLR200"},{"key":"97","doi-asserted-by":"crossref","unstructured":"97) Tsimikas S, Bergmark C, Beyer RW, Patel R, Pattison J, Miller E, Juliano J, Witztum JL: Temporal increases in plasma markers of oxidized low-density lipoprotein strongly reflect the presence of acute coronary syndromes. J Am Coll Cardiol, 2003; 41: 360-370","DOI":"10.1016\/S0735-1097(02)02769-9"},{"key":"98","doi-asserted-by":"crossref","unstructured":"98) Tsimikas S, Witztum JL, Miller ER, Sasiela WJ, Szarek M, Olsson AG, Schwartz GG: High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein bB-100 in patients with acute coronary syndromes in the miracl trial. Circulation, 2004; 110: 1406-1412","DOI":"10.1161\/01.CIR.0000141728.23033.B5"},{"key":"99","doi-asserted-by":"crossref","unstructured":"99) Lopes-Virella MF, McHenry MB, Lipsitz S, Yim E, Wilson PF, Lackland DT, Lyons T, Jenkins AJ, Virella G: Immune complexes containing modified lipoproteins are related to the progression of internal carotid intimamedia thickness in patients with type 1 diabetes. Atherosclerosis, 2007; 190: 359-369","DOI":"10.1016\/j.atherosclerosis.2006.02.007"},{"key":"100","doi-asserted-by":"crossref","unstructured":"100) Lopes-Virella MF, Hunt KJ, Baker NL, Lachin J, Nathan DM, Virella G: The levels of oxidized LDL and age-LDL in circulating immune complexes are strongly associated with increased levels of carotid intima-media thickness and its progression in type 1 diabetes. Diabetes, 2011; 60: 582-589","DOI":"10.2337\/db10-0915"},{"key":"101","doi-asserted-by":"crossref","unstructured":"101) Lopes-Virella MF, Baker NL, Hunt KJ, Lachin J, Nathan D, Virella G: Oxidized LDL immune complexes and coronary artery calcification in type 1 diabetes. Atherosclerosis, 2011; 214: 462-467","DOI":"10.1016\/j.atherosclerosis.2010.11.012"},{"key":"102","doi-asserted-by":"crossref","unstructured":"102) Holvoet P, Vanhaecke J, Janssens S, Van de Werf F, Collen D: Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease. Circulation, 1998; 98: 1487-1494","DOI":"10.1161\/01.CIR.98.15.1487"},{"key":"103","unstructured":"103) Fu D, Wu M, Chen Y, Du M, Zhang J, Li Y, Virella G, Wilson K, Boulton M, Ma J-X, Lopes-Virella MF, Chen J, Lyons TJ: Oxidized-LDL immunocomplexes are implicated in diabetic retinopathy. Diabetes, 2011; 60 (Suppl. 1): A53"},{"key":"104","doi-asserted-by":"crossref","unstructured":"104) Lopes-Virella MF, Baker N, Hunt K, Lyons T, A. J, Virella G, group DEs: High concentrations of age-LDL and oxidized LDL in circulating immune complexes is associated with progression of retinopathy in type 1 diabetes. Diabetes care, 2012; 35: 1333-1340","DOI":"10.2337\/dc11-2040"},{"key":"105","doi-asserted-by":"crossref","unstructured":"105) Virella G, Carter RE, Saad A, Crosswell EG, Game BA, Lopes-Virella MF: Distribution of IgM and IgG antibodies to oxidized LDL in immune complexes isolated from patients with type 1 diabetes and its relationship with nephropathy. Clin Immunol, 2008; 127: 394-400","DOI":"10.1016\/j.clim.2008.02.005"}],"container-title":["Journal of Atherosclerosis and Thrombosis"],"original-title":[],"language":"en","deposited":{"date-parts":[[2022,3,3]],"date-time":"2022-03-03T22:58:23Z","timestamp":1646348303000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/20\/10\/20_19281\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013]]},"references-count":105,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.5551\/jat.19281","relation":{},"ISSN":["1340-3478","1880-3873"],"issn-type":[{"value":"1340-3478","type":"print"},{"value":"1880-3873","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013]]}}}